1-4 of 4
Martin Sill, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Biomarkers for Clinical Response of Extracorporeal Photopheresis

Ming Ni, Lei Wang, MD, Angela Hückelhoven, PhD, Leopold Sellner, MD, Jean-Marc Hoffmann, Thomas Luft, MD PhD, Ute Hegenbart, Stefan Schönland, MD, Christian Kleist, PhD, Martin Sill, PhD, Bao-an Chen, Patrick Wuchter, MD, Volker Eckstein, PhD, William Hermann Krüger, MD PhD, Inken Hilgendorf, Arnon Nagler, MD, Carsten Müller-Tidow, Anthony D. Ho, Peter Dreger, MD, Michael Schmitt, MD PhD, Anita Schmitt, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3264.
https://doi.org/10.1182/blood.V130.Suppl_1.3264.3264
Published: 2017
Journal Articles

High CD52 mRNA Expression Is An Adverse Prognostic Factor In Fludarabine-Refractory CLL Treated With Alemtuzumab On The Gcllsg CLL2H Trial

Johannes Bloehdorn, MD, Martin Sill, PhD, Christian Langer, MD, Axel Benner, Dipl.Stat., Thorsten Zenz, MD, Andreas Bühler, MD, Raymonde Busch, PhD, Peter Dreger, MD, Ulrich Jäger, MD, Michael Hallek, M.D. Ph.D., Hartmut Döhner, MD, Stephan Stilgenbauer, MD
Journal: Blood
Blood (2013) 122 (21): 1618.
https://doi.org/10.1182/blood.V122.21.1618.1618
Published: 2013
Journal Articles

Systematic Mapping Of Drug and Pathway Sensitivity In Chronic Lymphocytic Leukemia Identifies Synthetic Lethal Interactions Of Mutant p53

Leopold Sellner, MD, Oles Malgorzata, Mikolaj Slabicki, PhD, Carolin Blume, Hüllein Jennifer, Tatjana Stolz, Martin Sill, PhD, Sascha Dietrich, MD, Olaf Merkel, PhD, Anna Jauch, PhD, Manfred Hensel, MD, Davide Rossi, Zirlik Katja, MD, Martina Seiffert, PhD, Anthony D. Ho, MD, von Kalle Christof, MD, Hanno Glimm, MD, Wolfgang Huber, PhD, Thorsten Zenz, MD
Journal: Blood
Blood (2013) 122 (21): 173.
https://doi.org/10.1182/blood.V122.21.173.173
Published: 2013
Journal Articles

Microrna Expression in Fludarabine-Refractory CLL Implicates Independent Mechanisms of Resistance and Is Associated with Response and Progression Free Survival After Alemtuzumab Treatment: Results From the CLL2H Trial.

Johannes Bloehdorn, MD, Martin Sill, PhD, Andreas Bühler, MD, Silja Mack, MSc, Doris Winter, Lars Bullinger, MD, PhD, Arefeh Rouhi, PhD, Florian Kuchenbauer, MD, PhD, Daniel Mertens, PhD, Axel Benner, Dipl.Stat., Michael Hallek, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD
Journal: Blood
Blood (2012) 120 (21): 2874.
https://doi.org/10.1182/blood.V120.21.2874.2874
Published: 2012